Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04494386 · ClinicalTrials.gov registry record · Phase 1
Umbilical Cord Lining Stem Cells (ULSC) in Patients With COVID-19 ARDS
A Phase 1 study, sponsored by Restem.
- Completed
- Registry status
- Phase 1
- Development phase
- 17
- Enrollment target
NCT04494386 is a Phase 1 study that has completed, run by Restem. The registered enrollment target is 17 participants.
The verdict
NCT04494386, a Phase 1 study, has completed, sponsored by Restem.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 17 participants
- Enrollment target
Study Summary
ULSC-CV-01 is a clinical trial that comprises both Phase 1 and Phase 2a, which will be conducted sequentially. This trial will evaluate the safety and potential efficacy of allogeneic Umbilical Cord Lining Stem Cells (ULSC), which are a type of umbilical cord tissue derived mesenchymal stem cells (MSC), with intravenous (IV) administration in hospitalized patients with acute respiratory distress syndrome (ARDS) due to COVID-19.
Interventions
- BIOLOGICAL Umbilical Cord Lining Stem Cells (ULSC)
- OTHER Placebo (carrier control)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2020-12-23 |
| Est. Completion | 2023-05-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04494386
The ClinicalTrials.gov registry entry for NCT04494386 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Restem, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Umbilical Cord Lining Stem Cells (ULSC) is the first listed.
NCT04494386 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04494386 about?
NCT04494386 is a clinical study titled "Umbilical Cord Lining Stem Cells (ULSC) in Patients With COVID-19 ARDS". ULSC-CV-01 is a clinical trial that comprises both Phase 1 and Phase 2a, which will be conducted sequentially. This trial will evaluate the safety and potential efficacy of allogeneic Umbilical Cord Lining Stem Cells (ULSC), which are a type of umbilical cord tissue derived mesenchymal stem cells (M...
What is the current status of trial NCT04494386?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 17 participants. The study started on 2020-12-23. Estimated completion is 2023-05-12.
What interventions are being tested in trial NCT04494386?
The interventions under investigation include: Umbilical Cord Lining Stem Cells (ULSC) (BIOLOGICAL), Placebo (carrier control) (OTHER).
Who is sponsoring clinical trial NCT04494386?
This trial is sponsored by Restem, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.